Global Radionuclide-conjugated Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Radionuclide-conjugated Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report is a detailed and comprehensive analysis for global Radionuclide-conjugated Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radionuclide-conjugated Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radionuclide-conjugated Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radionuclide-conjugated Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radionuclide-conjugated Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radionuclide-conjugated Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radionuclide-conjugated Drugs, with revenue, gross margin, and global market share of Radionuclide-conjugated Drugs from 2021 to 2026.
Chapter 3, the Radionuclide-conjugated Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radionuclide-conjugated Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radionuclide-conjugated Drugs.
Chapter 13, to describe Radionuclide-conjugated Drugs research findings and conclusion.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report is a detailed and comprehensive analysis for global Radionuclide-conjugated Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radionuclide-conjugated Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radionuclide-conjugated Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radionuclide-conjugated Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radionuclide-conjugated Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radionuclide-conjugated Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radionuclide-conjugated Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radionuclide-conjugated Drugs, with revenue, gross margin, and global market share of Radionuclide-conjugated Drugs from 2021 to 2026.
Chapter 3, the Radionuclide-conjugated Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radionuclide-conjugated Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radionuclide-conjugated Drugs.
Chapter 13, to describe Radionuclide-conjugated Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radionuclide-conjugated Drugs by Type
1.3.1 Overview: Global Radionuclide-conjugated Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Radionuclide-conjugated Drugs Consumption Value Market Share by Type in 2025
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Radionuclide-conjugated Drugs Market by Application
1.4.1 Overview: Global Radionuclide-conjugated Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Radionuclide-conjugated Drugs Market Size & Forecast
1.6 Global Radionuclide-conjugated Drugs Market Size and Forecast by Region
1.6.1 Global Radionuclide-conjugated Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Radionuclide-conjugated Drugs Market Size by Region, (2021-2032)
1.6.3 North America Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.4 Europe Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.6 South America Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Radionuclide-conjugated Drugs Product and Solutions
2.1.4 Bayer Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Radionuclide-conjugated Drugs Product and Solutions
2.2.4 Novartis Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Radionuclide-conjugated Drugs Product and Solutions
2.3.4 Lantheus Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Radionuclide-conjugated Drugs Product and Solutions
2.4.4 Aurobindo Pharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Radionuclide-conjugated Drugs Product and Solutions
2.5.4 Mundipharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Radionuclide-conjugated Drugs Product and Solutions
2.6.4 China Isotope & Radiation Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.7.4 Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Radionuclide-conjugated Drugs Product and Solutions
2.8.4 Gilead Sciences Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.9.4 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Radionuclide-conjugated Drugs Product and Solutions
2.10.4 Curasight Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Radionuclide-conjugated Drugs Product and Solutions
2.11.4 Nordic Nanovector Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Radionuclide-conjugated Drugs Product and Solutions
2.12.4 Philogen Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Radionuclide-conjugated Drugs Product and Solutions
2.13.4 RadioMedix Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.14.4 Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Radionuclide-conjugated Drugs Product and Solutions
2.15.4 Orano Med Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.16.4 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product and Solutions
2.17.4 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.18.4 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Radionuclide-conjugated Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Radionuclide-conjugated Drugs by Company Revenue
3.2.2 Top 3 Radionuclide-conjugated Drugs Players Market Share in 2025
3.2.3 Top 6 Radionuclide-conjugated Drugs Players Market Share in 2025
3.3 Radionuclide-conjugated Drugs Market: Overall Company Footprint Analysis
3.3.1 Radionuclide-conjugated Drugs Market: Region Footprint
3.3.2 Radionuclide-conjugated Drugs Market: Company Product Type Footprint
3.3.3 Radionuclide-conjugated Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Radionuclide-conjugated Drugs Consumption Value and Market Share by Type (2021-2026)
4.2 Global Radionuclide-conjugated Drugs Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global Radionuclide-conjugated Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
6.2 North America Radionuclide-conjugated Drugs Market Size by Application (2021-2032)
6.3 North America Radionuclide-conjugated Drugs Market Size by Country
6.3.1 North America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
6.3.2 United States Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
7.2 Europe Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
7.3 Europe Radionuclide-conjugated Drugs Market Size by Country
7.3.1 Europe Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.3 France Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region
8.3.1 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2021-2032)
8.3.2 China Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.5 India Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
9.2 South America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
9.3 South America Radionuclide-conjugated Drugs Market Size by Country
9.3.1 South America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country
10.3.1 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Radionuclide-conjugated Drugs Market Drivers
11.2 Radionuclide-conjugated Drugs Market Restraints
11.3 Radionuclide-conjugated Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Radionuclide-conjugated Drugs Industry Chain
12.2 Radionuclide-conjugated Drugs Upstream Analysis
12.3 Radionuclide-conjugated Drugs Midstream Analysis
12.4 Radionuclide-conjugated Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radionuclide-conjugated Drugs by Type
1.3.1 Overview: Global Radionuclide-conjugated Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Radionuclide-conjugated Drugs Consumption Value Market Share by Type in 2025
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Radionuclide-conjugated Drugs Market by Application
1.4.1 Overview: Global Radionuclide-conjugated Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Radionuclide-conjugated Drugs Market Size & Forecast
1.6 Global Radionuclide-conjugated Drugs Market Size and Forecast by Region
1.6.1 Global Radionuclide-conjugated Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Radionuclide-conjugated Drugs Market Size by Region, (2021-2032)
1.6.3 North America Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.4 Europe Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.6 South America Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Radionuclide-conjugated Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Radionuclide-conjugated Drugs Product and Solutions
2.1.4 Bayer Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Radionuclide-conjugated Drugs Product and Solutions
2.2.4 Novartis Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Radionuclide-conjugated Drugs Product and Solutions
2.3.4 Lantheus Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Radionuclide-conjugated Drugs Product and Solutions
2.4.4 Aurobindo Pharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Radionuclide-conjugated Drugs Product and Solutions
2.5.4 Mundipharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Radionuclide-conjugated Drugs Product and Solutions
2.6.4 China Isotope & Radiation Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.7.4 Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Radionuclide-conjugated Drugs Product and Solutions
2.8.4 Gilead Sciences Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.9.4 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Radionuclide-conjugated Drugs Product and Solutions
2.10.4 Curasight Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Radionuclide-conjugated Drugs Product and Solutions
2.11.4 Nordic Nanovector Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Radionuclide-conjugated Drugs Product and Solutions
2.12.4 Philogen Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Radionuclide-conjugated Drugs Product and Solutions
2.13.4 RadioMedix Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.14.4 Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Radionuclide-conjugated Drugs Product and Solutions
2.15.4 Orano Med Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.16.4 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product and Solutions
2.17.4 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
2.18.4 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Radionuclide-conjugated Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Radionuclide-conjugated Drugs by Company Revenue
3.2.2 Top 3 Radionuclide-conjugated Drugs Players Market Share in 2025
3.2.3 Top 6 Radionuclide-conjugated Drugs Players Market Share in 2025
3.3 Radionuclide-conjugated Drugs Market: Overall Company Footprint Analysis
3.3.1 Radionuclide-conjugated Drugs Market: Region Footprint
3.3.2 Radionuclide-conjugated Drugs Market: Company Product Type Footprint
3.3.3 Radionuclide-conjugated Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Radionuclide-conjugated Drugs Consumption Value and Market Share by Type (2021-2026)
4.2 Global Radionuclide-conjugated Drugs Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global Radionuclide-conjugated Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
6.2 North America Radionuclide-conjugated Drugs Market Size by Application (2021-2032)
6.3 North America Radionuclide-conjugated Drugs Market Size by Country
6.3.1 North America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
6.3.2 United States Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
7.2 Europe Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
7.3 Europe Radionuclide-conjugated Drugs Market Size by Country
7.3.1 Europe Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.3 France Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Radionuclide-conjugated Drugs Market Size by Region
8.3.1 Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2021-2032)
8.3.2 China Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.5 India Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
9.2 South America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
9.3 South America Radionuclide-conjugated Drugs Market Size by Country
9.3.1 South America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Country
10.3.1 Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE Radionuclide-conjugated Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Radionuclide-conjugated Drugs Market Drivers
11.2 Radionuclide-conjugated Drugs Market Restraints
11.3 Radionuclide-conjugated Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Radionuclide-conjugated Drugs Industry Chain
12.2 Radionuclide-conjugated Drugs Upstream Analysis
12.3 Radionuclide-conjugated Drugs Midstream Analysis
12.4 Radionuclide-conjugated Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Radionuclide-conjugated Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Radionuclide-conjugated Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Radionuclide-conjugated Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Radionuclide-conjugated Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Radionuclide-conjugated Drugs Product and Solutions
Table 8. Bayer Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Radionuclide-conjugated Drugs Product and Solutions
Table 13. Novartis Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Radionuclide-conjugated Drugs Product and Solutions
Table 18. Lantheus Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 20. Aurobindo Pharma Major Business
Table 21. Aurobindo Pharma Radionuclide-conjugated Drugs Product and Solutions
Table 22. Aurobindo Pharma Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Aurobindo Pharma Recent Developments and Future Plans
Table 24. Mundipharma Company Information, Head Office, and Major Competitors
Table 25. Mundipharma Major Business
Table 26. Mundipharma Radionuclide-conjugated Drugs Product and Solutions
Table 27. Mundipharma Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Mundipharma Recent Developments and Future Plans
Table 29. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 30. China Isotope & Radiation Major Business
Table 31. China Isotope & Radiation Radionuclide-conjugated Drugs Product and Solutions
Table 32. China Isotope & Radiation Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. China Isotope & Radiation Recent Developments and Future Plans
Table 34. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 35. Curium Pharmaceuticals Major Business
Table 36. Curium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 37. Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Curium Pharmaceuticals Recent Developments and Future Plans
Table 39. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 40. Gilead Sciences Major Business
Table 41. Gilead Sciences Radionuclide-conjugated Drugs Product and Solutions
Table 42. Gilead Sciences Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Gilead Sciences Recent Developments and Future Plans
Table 44. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 45. Clarity Pharmaceuticals Major Business
Table 46. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 47. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 49. Curasight Company Information, Head Office, and Major Competitors
Table 50. Curasight Major Business
Table 51. Curasight Radionuclide-conjugated Drugs Product and Solutions
Table 52. Curasight Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Curasight Recent Developments and Future Plans
Table 54. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 55. Nordic Nanovector Major Business
Table 56. Nordic Nanovector Radionuclide-conjugated Drugs Product and Solutions
Table 57. Nordic Nanovector Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Nordic Nanovector Recent Developments and Future Plans
Table 59. Philogen Company Information, Head Office, and Major Competitors
Table 60. Philogen Major Business
Table 61. Philogen Radionuclide-conjugated Drugs Product and Solutions
Table 62. Philogen Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Philogen Recent Developments and Future Plans
Table 64. RadioMedix Company Information, Head Office, and Major Competitors
Table 65. RadioMedix Major Business
Table 66. RadioMedix Radionuclide-conjugated Drugs Product and Solutions
Table 67. RadioMedix Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. RadioMedix Recent Developments and Future Plans
Table 69. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 70. Telix Pharmaceuticals Major Business
Table 71. Telix Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 72. Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. Telix Pharmaceuticals Recent Developments and Future Plans
Table 74. Orano Med Company Information, Head Office, and Major Competitors
Table 75. Orano Med Major Business
Table 76. Orano Med Radionuclide-conjugated Drugs Product and Solutions
Table 77. Orano Med Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Orano Med Recent Developments and Future Plans
Table 79. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 80. Actinium Pharmaceuticals Major Business
Table 81. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 82. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 84. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 85. Y-mAbs Therapeutics Major Business
Table 86. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product and Solutions
Table 87. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 89. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 90. Fusion Pharmaceuticals Major Business
Table 91. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 92. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 93. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 94. Global Radionuclide-conjugated Drugs Revenue (USD Million) by Players (2021-2026)
Table 95. Global Radionuclide-conjugated Drugs Revenue Share by Players (2021-2026)
Table 96. Breakdown of Radionuclide-conjugated Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 97. Market Position of Players in Radionuclide-conjugated Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 98. Head Office of Key Radionuclide-conjugated Drugs Players
Table 99. Radionuclide-conjugated Drugs Market: Company Product Type Footprint
Table 100. Radionuclide-conjugated Drugs Market: Company Product Application Footprint
Table 101. Radionuclide-conjugated Drugs New Market Entrants and Barriers to Market Entry
Table 102. Radionuclide-conjugated Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 103. Global Radionuclide-conjugated Drugs Consumption Value (USD Million) by Type (2021-2026)
Table 104. Global Radionuclide-conjugated Drugs Consumption Value Share by Type (2021-2026)
Table 105. Global Radionuclide-conjugated Drugs Consumption Value Forecast by Type (2027-2032)
Table 106. Global Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026)
Table 107. Global Radionuclide-conjugated Drugs Consumption Value Forecast by Application (2027-2032)
Table 108. North America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 109. North America Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 110. North America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 111. North America Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 112. North America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 113. North America Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Europe Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 115. Europe Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 116. Europe Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 117. Europe Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 118. Europe Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 119. Europe Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 120. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 121. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 122. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 123. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 124. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 125. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 126. South America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 127. South America Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 128. South America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 129. South America Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 130. South America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 131. South America Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 132. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 133. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 134. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 135. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 136. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 137. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 138. Global Key Players of Radionuclide-conjugated Drugs Upstream (Raw Materials)
Table 139. Global Radionuclide-conjugated Drugs Typical Customers
Table 1. Global Radionuclide-conjugated Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Radionuclide-conjugated Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Radionuclide-conjugated Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Radionuclide-conjugated Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Radionuclide-conjugated Drugs Product and Solutions
Table 8. Bayer Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Radionuclide-conjugated Drugs Product and Solutions
Table 13. Novartis Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Radionuclide-conjugated Drugs Product and Solutions
Table 18. Lantheus Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 20. Aurobindo Pharma Major Business
Table 21. Aurobindo Pharma Radionuclide-conjugated Drugs Product and Solutions
Table 22. Aurobindo Pharma Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Aurobindo Pharma Recent Developments and Future Plans
Table 24. Mundipharma Company Information, Head Office, and Major Competitors
Table 25. Mundipharma Major Business
Table 26. Mundipharma Radionuclide-conjugated Drugs Product and Solutions
Table 27. Mundipharma Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Mundipharma Recent Developments and Future Plans
Table 29. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 30. China Isotope & Radiation Major Business
Table 31. China Isotope & Radiation Radionuclide-conjugated Drugs Product and Solutions
Table 32. China Isotope & Radiation Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. China Isotope & Radiation Recent Developments and Future Plans
Table 34. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 35. Curium Pharmaceuticals Major Business
Table 36. Curium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 37. Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Curium Pharmaceuticals Recent Developments and Future Plans
Table 39. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 40. Gilead Sciences Major Business
Table 41. Gilead Sciences Radionuclide-conjugated Drugs Product and Solutions
Table 42. Gilead Sciences Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Gilead Sciences Recent Developments and Future Plans
Table 44. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 45. Clarity Pharmaceuticals Major Business
Table 46. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 47. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 49. Curasight Company Information, Head Office, and Major Competitors
Table 50. Curasight Major Business
Table 51. Curasight Radionuclide-conjugated Drugs Product and Solutions
Table 52. Curasight Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Curasight Recent Developments and Future Plans
Table 54. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 55. Nordic Nanovector Major Business
Table 56. Nordic Nanovector Radionuclide-conjugated Drugs Product and Solutions
Table 57. Nordic Nanovector Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Nordic Nanovector Recent Developments and Future Plans
Table 59. Philogen Company Information, Head Office, and Major Competitors
Table 60. Philogen Major Business
Table 61. Philogen Radionuclide-conjugated Drugs Product and Solutions
Table 62. Philogen Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Philogen Recent Developments and Future Plans
Table 64. RadioMedix Company Information, Head Office, and Major Competitors
Table 65. RadioMedix Major Business
Table 66. RadioMedix Radionuclide-conjugated Drugs Product and Solutions
Table 67. RadioMedix Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. RadioMedix Recent Developments and Future Plans
Table 69. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 70. Telix Pharmaceuticals Major Business
Table 71. Telix Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 72. Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. Telix Pharmaceuticals Recent Developments and Future Plans
Table 74. Orano Med Company Information, Head Office, and Major Competitors
Table 75. Orano Med Major Business
Table 76. Orano Med Radionuclide-conjugated Drugs Product and Solutions
Table 77. Orano Med Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Orano Med Recent Developments and Future Plans
Table 79. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 80. Actinium Pharmaceuticals Major Business
Table 81. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 82. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 84. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 85. Y-mAbs Therapeutics Major Business
Table 86. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product and Solutions
Table 87. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 89. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 90. Fusion Pharmaceuticals Major Business
Table 91. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product and Solutions
Table 92. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 93. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 94. Global Radionuclide-conjugated Drugs Revenue (USD Million) by Players (2021-2026)
Table 95. Global Radionuclide-conjugated Drugs Revenue Share by Players (2021-2026)
Table 96. Breakdown of Radionuclide-conjugated Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 97. Market Position of Players in Radionuclide-conjugated Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 98. Head Office of Key Radionuclide-conjugated Drugs Players
Table 99. Radionuclide-conjugated Drugs Market: Company Product Type Footprint
Table 100. Radionuclide-conjugated Drugs Market: Company Product Application Footprint
Table 101. Radionuclide-conjugated Drugs New Market Entrants and Barriers to Market Entry
Table 102. Radionuclide-conjugated Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 103. Global Radionuclide-conjugated Drugs Consumption Value (USD Million) by Type (2021-2026)
Table 104. Global Radionuclide-conjugated Drugs Consumption Value Share by Type (2021-2026)
Table 105. Global Radionuclide-conjugated Drugs Consumption Value Forecast by Type (2027-2032)
Table 106. Global Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026)
Table 107. Global Radionuclide-conjugated Drugs Consumption Value Forecast by Application (2027-2032)
Table 108. North America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 109. North America Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 110. North America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 111. North America Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 112. North America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 113. North America Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Europe Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 115. Europe Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 116. Europe Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 117. Europe Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 118. Europe Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 119. Europe Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 120. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 121. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 122. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 123. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 124. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 125. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 126. South America Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 127. South America Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 128. South America Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 129. South America Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 130. South America Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 131. South America Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 132. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 133. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 134. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 135. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 136. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 137. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 138. Global Key Players of Radionuclide-conjugated Drugs Upstream (Raw Materials)
Table 139. Global Radionuclide-conjugated Drugs Typical Customers
LIST OF FIGURES
Figure 1. Radionuclide-conjugated Drugs Picture
Figure 2. Global Radionuclide-conjugated Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Type in 2025
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Radionuclide-conjugated Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Radionuclide-conjugated Drugs Consumption Value Market Share by Application in 2025
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Radionuclide-conjugated Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 11. Global Radionuclide-conjugated Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 12. Global Market Radionuclide-conjugated Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 13. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Region (2021-2032)
Figure 14. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Region in 2025
Figure 15. North America Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. Europe Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 17. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. South America Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Company Three Recent Developments and Future Plans
Figure 21. Global Radionuclide-conjugated Drugs Revenue Share by Players in 2025
Figure 22. Radionuclide-conjugated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 23. Market Share of Radionuclide-conjugated Drugs by Player Revenue in 2025
Figure 24. Top 3 Radionuclide-conjugated Drugs Players Market Share in 2025
Figure 25. Top 6 Radionuclide-conjugated Drugs Players Market Share in 2025
Figure 26. Global Radionuclide-conjugated Drugs Consumption Value Share by Type (2021-2026)
Figure 27. Global Radionuclide-conjugated Drugs Market Share Forecast by Type (2027-2032)
Figure 28. Global Radionuclide-conjugated Drugs Consumption Value Share by Application (2021-2026)
Figure 29. Global Radionuclide-conjugated Drugs Market Share Forecast by Application (2027-2032)
Figure 30. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 31. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 32. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 33. United States Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 34. Canada Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 35. Mexico Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 37. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 38. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 39. Germany Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 40. France Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 41. United Kingdom Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Russia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Italy Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 45. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 46. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Region (2021-2032)
Figure 47. China Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Japan Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. South Korea Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. India Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Southeast Asia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Australia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 54. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 55. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 56. Brazil Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Argentina Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 59. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 60. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 61. Turkey Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Saudi Arabia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. UAE Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. Radionuclide-conjugated Drugs Market Drivers
Figure 65. Radionuclide-conjugated Drugs Market Restraints
Figure 66. Radionuclide-conjugated Drugs Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Radionuclide-conjugated Drugs Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. Radionuclide-conjugated Drugs Picture
Figure 2. Global Radionuclide-conjugated Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Type in 2025
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Radionuclide-conjugated Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Radionuclide-conjugated Drugs Consumption Value Market Share by Application in 2025
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Radionuclide-conjugated Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 11. Global Radionuclide-conjugated Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 12. Global Market Radionuclide-conjugated Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 13. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Region (2021-2032)
Figure 14. Global Radionuclide-conjugated Drugs Consumption Value Market Share by Region in 2025
Figure 15. North America Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. Europe Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 17. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. South America Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Company Three Recent Developments and Future Plans
Figure 21. Global Radionuclide-conjugated Drugs Revenue Share by Players in 2025
Figure 22. Radionuclide-conjugated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 23. Market Share of Radionuclide-conjugated Drugs by Player Revenue in 2025
Figure 24. Top 3 Radionuclide-conjugated Drugs Players Market Share in 2025
Figure 25. Top 6 Radionuclide-conjugated Drugs Players Market Share in 2025
Figure 26. Global Radionuclide-conjugated Drugs Consumption Value Share by Type (2021-2026)
Figure 27. Global Radionuclide-conjugated Drugs Market Share Forecast by Type (2027-2032)
Figure 28. Global Radionuclide-conjugated Drugs Consumption Value Share by Application (2021-2026)
Figure 29. Global Radionuclide-conjugated Drugs Market Share Forecast by Application (2027-2032)
Figure 30. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 31. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 32. North America Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 33. United States Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 34. Canada Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 35. Mexico Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 37. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 38. Europe Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 39. Germany Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 40. France Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 41. United Kingdom Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Russia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Italy Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 45. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 46. Asia-Pacific Radionuclide-conjugated Drugs Consumption Value Market Share by Region (2021-2032)
Figure 47. China Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Japan Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. South Korea Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. India Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Southeast Asia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Australia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 54. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 55. South America Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 56. Brazil Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Argentina Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Type (2021-2032)
Figure 59. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Application (2021-2032)
Figure 60. Middle East & Africa Radionuclide-conjugated Drugs Consumption Value Market Share by Country (2021-2032)
Figure 61. Turkey Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Saudi Arabia Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. UAE Radionuclide-conjugated Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. Radionuclide-conjugated Drugs Market Drivers
Figure 65. Radionuclide-conjugated Drugs Market Restraints
Figure 66. Radionuclide-conjugated Drugs Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Radionuclide-conjugated Drugs Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
